Point-of-care testing for early diagnosis and population screening of Alzheimer’s disease: Recent advances and perspectives
- 23 March 2026
- journal article
- Published by Elsevier in Nano Today
- Vol. 69
Abstract
No abstract availableFunding Information
- National Institutes of Health (R33AI147419)
- National Science Foundation (2528103)
- National Science Foundation (2319913)
- National Sleep Foundation
This publication has 230 references indexed in Scilit:
- Elecsys CSF AD immunoassays: Sample stability for a new pre‐analytical protocol for fresh CSFAlzheimer's & Dementia, 2025
- Multianalyte Nanopore Detection of Alzheimer's Disease Biomarkers: A Label‐Free Platform with Improved Sensitivity and Range (Adv. Healthcare Mater. 16/2025)Advanced Healthcare Materials, 2025
- Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratiosAlzheimer's & Dementia, 2025
- The role of neuropsychological assessment in the evaluation of patients with cognitive‐behavioral change due to suspected Alzheimer's disease and other causes of cognitive impairment and dementiaAlzheimer's & Dementia, 2024
- Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkersAlzheimer's & Dementia, 2024
- An Ultrasensitive Molecularly Imprinted Point‐Of‐Care Electrochemical Sensor for Detection of Glial Fibrillary Acidic ProteinAdvanced Healthcare Materials, 2024
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohortAlzheimer's & Dementia, 2022
- PlyAB Nanopores Detect Single Amino Acid Differences in Folded Haemoglobin from Blood**Angewandte Chemie International Edition, 2022
- Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive OutcomesJAMA Neurology, 2021